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RESEARCH
Effectiveness of text message based, diabetes self management 
support programme (SMS4BG): two arm, parallel randomised 
controlled trial
Rosie Dobson,1 Robyn Whittaker,1,2 Yannan Jiang,1 Ralph Maddison,3 Matthew Shepherd,4  
Catherine McNamara,5 Richard Cutfield,5 Manish Khanolkar,6 Rinki Murphy6,7
ABSTRACT
OBJECTIVE
To determine the effectiveness of a theoretically 
based and individually tailored, text message based, 
diabetes self management support intervention 
(SMS4BG) in adults with poorly controlled diabetes.
DESIGN
Nine month, two arm, parallel randomised controlled 
trial.
SETTING
Primary and secondary healthcare services in New 
Zealand.
PARTICIPANTS
366 participants aged 16 years and over with poorly 
controlled type 1 or type 2 diabetes (HbA1c ≥65 
mmol/mol or 8%) randomised between June 2015 and 
November 2016 (n=183 intervention, n=183 control).
INTERVENTIONS
The intervention group received a tailored package 
of text messages for up to nine months in addition 
to usual care. Text messages provided information, 
support, motivation, and reminders related to 
diabetes self management and lifestyle behaviours. 
The control group received usual care. Messages 
were delivered by a specifically designed automated 
content management system.
MAIN OUTCOME MEASURES
Primary outcome measure was change in glycaemic 
control (HbA1c) from baseline to nine months. 
Secondary outcomes included change in HbA1c at 
three and six months, and self efficacy, diabetes self 
care behaviours, diabetes distress, perceptions and 
beliefs about diabetes, health related quality of life, 
perceived support for diabetes management, and 
intervention engagement and satisfaction at nine 
months. Regression models adjusted for baseline 
outcome, health district category, diabetes type, and 
ethnicity.
RESULTS
The reduction in HbA1c at nine months was 
significantly greater in the intervention group (mean 
−8.85 mmol/mol (standard deviation 14.84)) than 
in the control group (−3.96 mmol/mol (17.02); 
adjusted mean difference −4.23 (95% confidence 
interval −7.30 to −1.15), P=0.007). Of 21 secondary 
outcomes, only four showed statistically significant 
improvements in favour of the intervention group at 
nine months. Significant improvements were seen for 
foot care behaviour (adjusted mean difference 0.85 
(95% confidence interval 0.40 to 1.29), P<0.001), 
overall diabetes support (0.26 (0.03 to 0.50), 
P=0.03), health status on the EQ-5D visual analogue 
scale (4.38 (0.44 to 8.33), P=0.03), and perceptions 
of illness identity (−0.54 (−1.04 to −0.03), P=0.04). 
High levels of satisfaction with SMS4BG were found, 
with 161 (95%) of 169 participants reporting it to 
be useful, and 164 (97%) willing to recommend the 
programme to other people with diabetes.
CONCLUSION
A tailored, text message based, self management 
support programme resulted in modest improvements 
in glycaemic control in adults with poorly controlled 
diabetes. Although the clinical significance of these 
results is unclear, the findings support further 
investigation into the use of SMS4BG and other text 
message based support for this patient population.
TRIAL REGISTRATION
Australian New Zealand Clinical Trials Registry 
ACTRN12614001232628.
Introduction
The growing prevalence of diabetes is considered to be 
one of the biggest global health issues.1 People of ethnic 
minorities, including Pacific and Māori (New Zealand 
indigenous population) groups, are particularly 
vulnerable to the development of diabetes, experience 
poorer control, and increased rates of complications.2-6 
In New Zealand, 29% of patients with diabetes were 
found to have HbA1c levels indicative of poor control 
(≥65 mmol/mol or 8%), putting them at risk for the 
development of debilitating and costly complications.7 
Diabetes complications can be prevented or delayed 
with good blood glucose control, which is not only 
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WhAT IS AlReAdy knoWn on ThIS TopIC
Effective diabetes self management support is vital to address the increase in 
costly and debilitating long term complications associated with poor diabetes 
control
Text messages (SMS) are an ideal tool for the delivery of self management 
support
The effectiveness of SMS for the delivery of diabetes self management support to 
individuals with poorly controlled diabetes is not known
WhAT ThIS STudy AddS
Text messaging is well received and has potential to be effective for the 
delivery of self management support to people with poorly controlled diabetes, 
warranting further investigation
SMS interventions have the potential to make culturally appropriate and 
personalised self management support accessible to nearly all people with 
diabetes, regardless of location
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advantageous for a person’s quality of life but also will 
substantially reduce healthcare costs associated with 
treating or managing the complications.8-12
The flexibility of mobile phones and their adoption 
into everyday life mean that they are an ideal tool in 
supporting people with diabetes whose condition 
needs constant management. Mobile phones, which 
have been used effectively to support diabetes 
management,13-16 offer an ideal avenue for providing 
care at the patient’s desired intensity. Additionally, 
they can provide effective methods of support to 
patients in rural and remote locations where access 
to healthcare providers can be limited.17 18 Although 
there is growing support for the use of mobile 
health (mHealth) in diabetes, there is increasing 
evidence of a digital divide, with lower use of some 
technologies in specific population groups.19 20 
These groups include people who have low health 
literacy,21 have low income,22-24 and are members 
of ethnic minorities.25  26 Contributing factors 
include low technology literacy, mismatch between 
individual needs and the available tools, lack of local 
information, cost, literacy and language barriers, and 
lack of cultural appropriateness.27 For mHealth tools 
to be used to manage poor diabetes control, they need 
to be designed to the needs and preferences of those 
people who need the greatest support by considering 
these factors.
The SMS4BG (self management support for blood 
glucose) intervention was developed to address 
the need for innovative solutions to support self 
management in adults with poorly controlled 
diabetes.28 The individually tailored intervention 
provides information and support designed to 
motivate a person to engage in the behaviours required 
to manage their diabetes effectively for long term 
health improvement. The development of SMS4BG 
followed the mHealth Development and Evaluation 
Framework29 (including extensive formative work and 
end user engagement to ensure that it met the needs 
of the population it was designed to reach) is evidence 
based and theoretically grounded. A previous pilot 
study found SMS4BG to be acceptable and perceived 
it as useful.28 This study aimed to determine the 
effectiveness of the mHealth diabetes self management 
support programme—SMS4BG in adults with poorly 
controlled type 1 or type 2 diabetes, in addition to their 
usual diabetes care.
Methods
Study design
A nine month, two arm, parallel, randomised 
controlled trial was conducted in adults with poorly 
controlled diabetes between June 2015 and August 
2017. The study received ethical approval from the 
Health and Disability Ethics Committee (14/STH/162), 
and the protocol was published30 and registered with 
the Australian New Zealand Clinical Trials Registry 
(ACTRN12614001232628). Trial development and 
reporting was guided by the CONSORT31 and CONSORT 
EHEALTH32 statements.
Participants
Participants were referred to the study by healthcare 
professionals at their primary and secondary care 
centres across New Zealand. Additionally, participants 
could self refer to the study. Eligible participants 
were English speaking adults aged 16 years and over 
with poorly controlled type 1 or 2 diabetes (defined 
as glycated haemoglobin (HbA1c) concentration 
≥65 mmol/mol or 8% in the preceding nine months). 
The initial protocol required HbA1c concentration 
above the cutoff level within the past three months, 
but after feedback from patients and clinicians, this 
period was extended to nine months to ensure a 
greater reach across those people not having regular 
tests. Participants required access to a mobile phone 
and needed to be available for the nine month study 
duration.
Randomisation and blinding
Eligible participants were randomised to either 
an intervention or control group in a 1:1 ratio. 
Randomisation was stratified by health district category 
(high urban or high rural/remote), diabetes type (1 or 
2), and ethnicity (Māori and Pacific, or non-Māori/non-
Pacific). The randomisation sequence was generated 
by computer programme using variable block sizes 
of two or four, and overseen by the study statistician. 
Following participant consent and completion 
of the baseline interview, the research assistant 
then randomised the participant to intervention or 
control, using the REDCap randomisation module. 
The REDCap randomisation module ensured that 
treatment allocation was concealed until the point of 
randomisation. Due to the nature of the intervention, 
participants were aware of their treatment allocation. 
Research assistants conducting the phone interviews 
were also aware of the treatment allocation. However, 
the objective primary outcome was measured by 
blinded assessors throughout the study period.
Procedures
Participants who were referred to the study by clinicians 
or who self referred were contacted by a research 
assistant via phone to discuss the study and confirm 
eligibility. All eligible participants completed informed 
consent followed by baseline assessment over the 
phone with a research assistant before randomisation. 
All participants continued with their usual diabetes 
care including all medical visits, tests, and diabetes 
support programmes throughout the study. In addition, 
the intervention group received SMS4BG. Control 
participants received usual care only. All participants 
completed a follow-up phone interview nine months 
after randomisation (within three weeks of the nine 
month date). HbA1c blood tests (at baseline, three, six, 
and nine months) were undertaken through standard 
care and results obtained through medical records.
Intervention
SMS4BG is an automated self management support 
programme delivered by SMS (short messaging 
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service) to motivate and support people to engage 
in the behaviours needed for successful diabetes 
management. The programme was tailored by the 
needs and goals of the individual, and demographic 
factors. As well as core motivational and support 
messages (in Māori, Pacific, or non-Māori/Pacific 
cultural versions), participants could opt to receive 
additional modules including those for: insulin 
control, young adult support, smoking cessation, 
lifestyle behaviour (exercise, healthy eating, or stress/
mood management), and foot care (further module 
details in supplementary table 1).
Participants could choose to receive blood glucose 
monitoring reminders to which they could reply by 
sending in their result by text message. They could 
then view their results graphically over time on a 
password protected website. If they were identified 
as not having access to the internet at baseline they 
were mailed their graphs once a month. All messages 
were delivered in English although the Māori version 
included keywords in Te Reo Māori and the Pacific 
version had keywords in either Samoan or Tongan 
dependent on ethnicity. Examples of SMS4BG 
messages can be seen in the box. Participants were 
able to select the timing of messages and reminders, 
and identify the names of their support people and 
motivations for incorporation into the messages. 
The duration of the programme was also tailored 
to individual preferences. At three and six months, 
participants received a message asking if they would 
like to continue the programme for an additional three 
months, and had the opportunity to reselect their 
modules receiving up to a maximum nine months of 
messages. Participants could stop their messages by 
texting the word “STOP” or put messages on hold by 
texting “HOLIDAY.”
The message delivery was managed by our 
content management system, with messages sent 
and received through a gateway company to allow 
for participants to be registered with any mobile 
network. Sending and receiving messages was free 
for participants. The system maintained logs of all 
outgoing and incoming messages. Further details of 
the intervention can be seen in the published pilot 
study,28 and protocol.30
Primary and secondary outcomes
The primary outcome measure was change in glycaemic 
control from baseline to nine months’ follow-up, 
measured as HbA1c (in mmol/mol, or equivalently in 
%). Secondary outcome measures included change 
in HbA1c at three and six months’ follow-up, and the 
following outcomes at nine months: 
•   Self efficacy for diabetes management (Stanford self 
efficacy for diabetes scale (SEDM)33)
•   Diabetes self care behaviours including diet (general 
and specific), exercise, blood glucose monitoring, 
and foot care (summary of diabetes self care 
activities (SDSCA) measure34)
•   Presence  of  diabetes  related  distress  (two  item 
diabetes distress scale (DDS2)35)
•   Perceptions and beliefs about diabetes (brief illness 
perception questionnaire (BIPQ)36)
•   Health related quality of life (EQ-5D (index score and 
visual analogue scale (VAS))37)
•   Perceived  social  support  for  diabetes management 
(measured by use of a four item measure developed 
for this study assessing overall support, appraisal 
support, emotional support, and advice/information 
support; protocol paper provides measure details30). 
Cost effectiveness as well as healthcare use was 
assessed during the study period compared with 
the nine months before randomisation (presented 
separately). We measured patient engagement and 
satisfaction with the intervention using semistructured 
interviews and data from the content management 
system. The secondary outcomes health related quality 
of life and perceived social support were not included 
Box: Examples of SMS4BG text messages
Core message—Maori version
Kia ora. Control of your glucose levels involves eating the right kai, exercise & taking your medication. Your whānau, doctor & nurse can help you
Young adult message
Unsure whether to tell your friends/boyfriend/girlfriend about diabetes? This can be tough but people who care about you will want to know & 
support you
Smoking cessation message
[hi] [name]. Good management of your diabetes & your future health includes not smoking, call Quitline on 0800 778 778 for support
Healthy eating message
Healthy eating is an important part of your diabetes treatment and it will help you in controlling your blood glucose levels
Stress and mood management message
[hi] [name]. Make sure you have fun activities scheduled regularly. Doing something enjoyable helps reduce stress & improves mood
Blood glucose monitoring reminder
[hi] [name]. Just a reminder it is time to check your blood glucose. Reply with the result
Foot care message
Looking after your feet will help to prevent issues in the future. Check your feet daily & contact your doctor, nurse or podiatrist if there are changes
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in the initial trial registration but added before 
commencing the trial.
Statistical analysis
As published in the protocol, a sample size of 500 
participants (250 per arm) was estimated to provide 
90% power at the 5% significance level to detect a 
clinically meaningful group difference of 0.5% (5.5 
mmol/mol) in HbA1c at nine months, assuming a 
standard deviation of 1.7% (18.6 mmol/mol). Despite 
extensive efforts, recruitment for the study was slower 
than expected, and with the limited overall study 
period available, a post hoc power calculation was 
conducted in September 2016. A revised sample size 
of 366 participants (183 per arm) was targeted, which 
would provide 80% power to detect the same effect 
size under the same assumptions.
Statistical analyses were performed by SAS version 
9.4 (SAS Institute). All statistical tests were two sided 
at a 5% significance level. Analyses were performed 
on the principle of intention to treat, including all 
randomised participants who provided at least one valid 
measure on the primary outcome after randomisation. 
Demographics and baseline characteristics of all 
participants were first summarised by treatment group 
with descriptive statistics. No formal statistical tests 
were conducted at baseline, because any baseline 
imbalance observed between two groups could have 
occurred by chance with randomisation. 
We summarised the primary and secondary outcomes 
using descriptive statistics at each scheduled visit. 
A random effects mixed model was used to evaluate 
the effect of intervention on HbA1c at three, six, and 
nine months’ follow-up, adjusting for baseline HbA1c 
and stratification factors and accounting for repeated 
measures over time. Model adjusted mean differences 
in HbA1c between the two groups were estimated at 
each visit, by including an interaction term between 
treatment and month. Missing data on the primary 
outcome were taken into account in modelling based 
on the missing at random assumption. Both 95% 
confidence intervals and P values were reported. 
Treatment effects sizes were also compared between 
important subgroups considered in stratification, 
including diabetes type (1 and 2), ethnicity (Māori/
Pacific and non-Māori/non-Pacific), and region (urban 
and rural). For other secondary outcomes measured 
at nine months, we used generalised linear regression 
models with same covariate adjustment using a link 
function appropriate to the distribution of outcomes. 
Model adjusted estimates on the treatment difference 
between the two groups at nine months were reported, 
together with 95% confidence intervals and P values. 
No imputation was considered on secondary outcomes.
Patient involvement
Patients were involved in all stages of the study, 
including the initial conceptualisation and formative 
work leading to the development of SMS4BG (for more 
information, see the development paper28). Patient 
feedback informed the intervention modality, purpose, 
and structure, and patients reviewed intervention 
content before it was finalised. Patient feedback on the 
acceptability of SMS4BG through the pilot study28 led to 
improvements to the intervention including additional 
modules, the option for feedback graphs to be posted, 
additional tailoring variables, and a longer duration of 
intervention. Patient feedback also informed the design 
of this trial—specifically its duration, the inclusion 
criteria, and recruitment methods. Additionally, 
patients contributed to workshops of key stakeholders 
held to discuss interpretation, dissemination of the 
findings, and potential implementation. We have 
thanked all participants for their involvement and they 
will be given access to all published results when these 
are made publicly available.
Results
A total of 793 individuals were referred to the study 
and assessed for eligibility between June 2015 and 
November 2016. Of these, 366 were randomised to 
the intervention and control groups (n=183 each; 
fig  1). The final nine month follow-up assessments 
were completed in August 2017, with loss to follow-up 
(that is, no follow-up data on any outcome) low in both 
groups (overall 7/366=2%). A total of 12 participants 
(six per group) were excluded from the primary outcome 
analysis because of no follow-up HbA1c results after 
randomisation. Baseline characteristics of participants 
are presented in table 1, and no adverse events were 
recorded from the study or protocol deviations.
Primary outcome
The main treatment effect on the primary outcome 
is presented in table 2. The reduction in HbA1c from 
baseline to nine month follow-up was significantly 
greater in the intervention group than in the control 
group (mean −8.85 mmol/mol (standard deviation 
14.84) v −3.96 mmol/mol (17.02), adjusted mean 
difference −4.23 (95% confidence interval −7.30 to 
−1.15), P=0.007). The adjusted mean difference on 
change in HbA1c at three and six months were −4.76 
(−8.10 to −1.43), P=0.005) and −2.36 (−5.75 to 1.04), 
P=0.17), respectively (table 2).
A decrease in HbA1c from baseline to nine 
month follow-up was observed in 75% (132/177) 
of intervention participants compared with 59% 
(105/177) of control participants (χ2 test, P=0.01). At 
nine months, 27% (48/177) of intervention and 17% 
(30/177) of control participants had HbA1c levels 
dropping to below 65 mmol/mol (P=0.024).
We saw no significant interaction between 
the treatment group and any of the prespecified 
subgroups: type 1 versus type 2 diabetes (P=0.82), 
non-Māori/non-Pacific versus Māori/Pacific ethnicity 
(P=0.60), high urban versus high rural/remote region 
(P=0.38). Adjusted mean differences on change in 
HbA1c from baseline to nine months for patients with 
type 1 and type 2 diabetes were −5.75 mmol/mol (95% 
confidence interval −10.08 to −1.43, P=0.009) and 
−3.64 mmol/mol (−7.72 to 0.44, P=0.08), respectively. 
Adjusted mean differences for non-Māori/non-Pacific 
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and Māori/Pacific people were −4.97 mmol/mol (−8.51 
to −1.43, P=0.006) and −3.21 mmol/mol (−9.11 to 
2.70, P=0.28), respectively. Adjusted mean differences 
for participants living in high urban and high rural/
remote areas were −4.54 mmol/mol (−8.40 to −0.68, 
P=0.02) and −3.94 mmol/mol (−9.00 to 1.12, P=0.13), 
respectively (table 3).
Secondary outcomes
The main effect of the intervention on secondary 
outcomes are presented in table 4. No significant 
differences were observed between the two groups 
for self efficacy (SEDM). A significant improvement in 
foot care behaviour was seen in the intervention group 
compared with the control group (adjusted mean 
difference 0.85 (95% confidence interval 0.40 to 1.29), 
P<0.001) but no significant group differences were 
observed for diet (general or specific), exercise, blood 
glucose testing, and smoking behaviours (SDSCA). 
No significant group differences were observed for 
diabetes distress (DDS2).
In relation to perceptions and beliefs about 
diabetes, a significant reduction in illness identity 
(how much patients experience diabetes related 
symptoms) on the BIPQ was observed in favour of 
the intervention (adjusted mean difference −0.54 
(95% confidence interval −1.04 to −0.03), P=0.04). 
However, we saw no significant group differences 
for perceptions of consequences, timeline, control, 
concern, emotions, and illness comprehensibility. A 
significant improvement in health status on the EQ-5D 
VAS was observed in favour of the intervention (4.38 
(0.44 to 8.33), P=0.03) but no significant differences 
were observed between groups for the quality of 
life index score. Finally, the measure of perceived 
support for diabetes management showed a significant 
improvement between the groups in how supported 
the participants felt in relation to their diabetes 
management overall (0.26 (0.03 to 0.50), P=0.03) 
but no significant group differences on appraisal, 
emotional, and informational support.
Participant satisfaction and acceptability
Among the intervention participants, 169 (92%) 
completed questions at follow-up about satisfaction 
and acceptability of the intervention (table 5). 
Participants reported high levels of satisfaction with 
SMS4BG, and all but two participants thought that 
text messaging was a good way to deliver this type of 
support. Ten participants reported technical issues 
while receiving the intervention, most commonly 
issues replying to the messages (n=4), issues accessing 
graphs (n=2), and mobile reception issues (n=2).
Participant engagement
Owing to individual tailoring, participants in the 
intervention group received varying numbers of 
messages. Half the participants (92/183) received 
messages for three months, an additional 18% 
(33/183) chose to continue the messages for six 
months, and the remaining 32% (58/183) chose to 
continue the messages to the maximum nine months. 
Only three participants chose to stop their messages 
early. A total number of 76 523 messages were sent 
by the system to participants (median number of 
messages per participant 242 (interquartile range 
Table 1 | Baseline characteristics of participants. Data are number (%) of participants 
unless stated otherwise
Characteristic Intervention group (n=183) Control group (n=183)
Male sex 92 (50) 97 (53)
Ethnicity 
 Māori 37 (20) 46 (25)
 Pacific 29 (16) 20 (11)
 Asian 8 (4) 12 (7)
 New Zealand European 93 (51) 88 (48)
 Other 16 (9) 17 (9)
Ethnicity category 
 Māori/Pacific 66 (36) 66 (36)
 Non-Māori/non-Pacific 117 (64) 117 (64)
Diabetes type 
 Type 1 65 (36) 64 (35)
 Type 2 118 (65) 119 (65)
Location 
 High urban 125 (68) 117 (64)
 High rural/remote 58 (32) 66 (36)
Smoking status 
 Smoker 29 (16) 35 (19)
 Non-smoker 154 (84) 148 (81)
Treatment: insulin 142 (78) 145 (79)
Referral source 
 Primary care 72 (39) 77 (42)
 Secondary care 106 (58) 105 (57)
 Self referred 5 (3) 1 (1)
Age group 
 16-24 years 25 (14) 21 (12)
 25-49 years 66 (36) 65 (36)
 50-64 years 73 (40) 77 (42)
 ≥65 years 19 (10) 20 (11)
Age (years), mean (SD) 47 (15) 47 (15)
Time since diagnosis (years), mean (SD) 13 (11) 12 (9)
SD=standard deviation.
Allocated to standard care alone (n=183)
Received allocated treatment (n=183)
Allocated to SMS4BG (n=183)
Received allocated treatment (n=183)
Total analysed (n=177)
Excluded from analysis (n=6)
Total analysed (n=177)
Excluded from analysis (n=6)
Assessed for eligibility (n=793)
Randomised (n=366)
Lost to follow-up (n=2):
  Withdrew participation from study (n=1)
  Unable to contact (n=1)
Discontinued allocated treatment (n=0)
Lost to follow-up (n=5):
  Unable to contact (n=4)
  Deceased (n=1)
Discontinued allocated treatment (n=3):
  Perceived intervention not useful (n=2)
  Health deteriorated (unrelated) (n=1)
Excluded (n=427):
  Not meeting inclusion criteria (n=79)
  Declined to participate (n=192)
  Unable to be contacted (n=118)
  Other reasons (n=38)
Fig 1 | Trial registration flowchart
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122-511; range 14-2050)), and 16 251 messages 
of blood glucose results were sent into the system 
by participants receiving the reminders (68 (1-169; 
0-917)).
discussion
This study found that a tailored, theoretically based, 
SMS based, diabetes self management support 
programme led to modest improvements in glycaemic 
control. The effects of intervention were also seen 
in four of 21 secondary outcomes, including foot 
care behaviour and ratings of diabetes support. The 
programme showed a high level of acceptability with 
the overwhelming majority of participants finding the 
intervention useful and willing to recommend it to 
others.
It is well documented that any reduction in HbA1c 
is likely to be associated with a decrease in the risk 
of diabetic complications.38 Reductions in HbA1c are 
much more clinically important at higher levels, given 
that the association between vascular complications 
and HbA1c is non-linear and that similar reductions 
at lower HbA1c levels have much less effect.38-40 In a 
less ethnically diverse population of people with type 2 
diabetes who had levels of HbA1c higher than 6.5% (53 
mmol/mol), a decrease of 1% (11 mmol/mol) has been 
found to result in reduced microvascular complications 
by 37%, myocardial infarction by 14%, and risk of 
Table 2 | Treatment effect on primary outcome (HbA1c (mmol/mol)). Data are mean (standard deviation) unless stated otherwise
Intervention (n=177) Control (n=177)
Unadjusted mean  
difference (95% CI)* P for difference
Adjusted mean  
difference (95% CI)* P for difference
Baseline 86.37 (17.83) 83.30 (14.80) — — — — 
Change from baseline 
at 3 months
−8.70 (14.61) −2.73 (15.07) −5.89 (−9.41 to −2.36) 0.001 −4.76 (−8.10 to −1.43) 0.005
Change from baseline 
at 6 months
−7.16 (14.14) −4.93 (13.97) −3.05 (−6.63 to 0.54) 0.10 −2.36 (−5.75 to 1.04) 0.17
Change from baseline 
at 9 months
−8.85 (14.84) −3.96 (17.02) −5.24 (−8.52 to −1.97) 0.002 −4.23 (−7.30 to −1.15) 0.007
*Random effects mixed model without and with adjustment for baseline outcome, diabetes type, ethnicity, and region. Both treatment group and visit were included in the model with their 
interaction term. A random participant effect was added to account for repeated measures on same participant.
Table 3 | Treatment effect on primary outcome (HbA1c (mmol/mol)), by key subgroups. Data are mean (standard deviation) unless stated otherwise
Intervention (n=177) Control (n=177) Adjusted mean difference (95% CI)* P for difference
Diabetes type
Type 1
 Baseline 87.55 (18.95) 82.64 (12.34)
 Change from baseline at 3 months −8.84 (11.15) −1.28 (12.33) −7.67 (−12.45 to −2.88) 0.002
 Change from baseline at 6 months −3.76 (12.41) −3.02 (9.66) −1.05 (−5.92 to 3.82) 0.67
 Change from baseline at 9 months −7.70 (12.05) −1.66 (11.92) −5.75 (−10.08 to −1.43) 0.009
Type 2
 Baseline 85.73 (17.24) 83.65 (15.98)
 Change from baseline at 3 months −8.62 (16.23) −3.53 (16.41) −3.42 (−7.82 to 0.98) 0.13
 Change from baseline at 6 months −9.13 (14.78) −5.90 (15.70) −3.32 (−7.80 to 1.16) 0.15
 Change from baseline at 9 months −9.49 (16.19) −5.24 (19.21) −3.64 (−7.72 to 0.44) 0.08
Ethnicity
Māori/Pacific
 Baseline 91.08 (19.95) 85.17 (13.56)
 Change from baseline at 3 months −8.42 (15.84) −1.87 (17.20) −5.36 (−11.80 to 1.07) 0.10
 Change from baseline at 6 months −6.11 (14.86) −5.00 (14.69) −0.77 (−7.31 to 5.78) 0.82
 Change from baseline at 9 months −7.91 (18.11) −3.29 (17.22) −3.21 (−9.11 to 2.70) 0.28
Non-Māori/non-Pacific
 Baseline 83.73 (16.02) 82.24 (15.38)
 Change from baseline at 3 months −8.85 (13.98) −3.13 (14.04) −4.50 (−8.33 to −0.67) 0.02
 Change from baseline at 6 months −7.64 (13.88) −4.88 (13.64) −3.29 (−7.19 to 0.61) 0.10
 Change from baseline at 9 months −9.39 (12.70) −4.33 (16.99) −4.97 (−8.51 to −1.43) 0.006
Location
High rural/remote
 Baseline 85.21 (18.91) 83.12 (17.13)
 Change from baseline at 3 months −5.38 (14.13) −2.07 (15.05) −1.34 (−6.89 to 4.21) 0.63
 Change from baseline at 6 months −7.52 (13.88) −6.38 (15.77) 0.14 (−5.53 to 5.80) 0.96
 Change from baseline at 9 months −9.72 (16.32) −5.42 (17.21) −3.94 (−9.00 to 1.12) 0.13
High urban
 Baseline 86.92 (17.37) 83.39 (13.35)
 Change from baseline at 3 months −10.20 (14.66) −3.06 (15.17) −6.53 (−10.69 to −2.37) 0.002
 Change from baseline at 6 months −7.01 (14.34) −4.15 (12.95) −3.62 (−7.84 to 0.60) 0.09
 Change from baseline at 9 months −8.40 (14.07) −3.18 (16.95) −4.54 (−8.40 to −0.68) 0.02
*Random effects mixed model adjusted for baseline outcome, diabetes type, ethnicity, and region. Both treatment group and visit were included in the model with their interaction term. 
A random participant effect was added to account for repeated measures on same participant. 
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death by 21%.38 A total of 75% of participants in the 
intervention group experienced a decrease in HbA1c 
at nine months, with a mean reduction in HbA1c of 
8.9 mmol/mol (0.8%) from baseline, and a significant 
group difference of 4.2 mmol/mol (0.4%) in favour of 
the intervention. Therefore, the results in this study 
have potential to be clinically relevant in reducing the 
risk of vascular complications and death, although 
further investigation is needed.
The average reduction of 4.2 mmol/mol (0.4%) 
in HbA1c seen in this study did not reach the level 
chosen to signify clinical significance in the initial 
power calculation (5.5 mmol/mol (0.5%) reduction 
in HbA1c). Therefore, this study is unable to conclude 
that the effects of the SMS4BG intervention are 
clinically significant. Although further investigation 
is needed, we believe the results have the potential 
to still be clinically relevant in practice, particularly 
among individuals with high levels of HbA1c, such 
as the participants with poorly controlled diabetes in 
this study. The unadjusted group difference on change 
in HbA1c from baseline was −5.89, −3.05 and −5.24 
mmol/mol at three, six, and nine months, respectively. 
The main analysis, with adjustment for baseline 
value and stratification factors, showed a smaller 
treatment effect, although both results were significant 
at three and nine months. Similar results were found 
across major subgroups of interest despite the fact 
that these analyses were not specifically powered. 
These consistent findings led us to believe that the 
intervention shows promising effects on treating 
people with poorly controlled diabetes and warrants 
further investigation.
This study contributes to the evidence around the 
use of SMS to support diabetes management.13-15 The 
improvements in HbA1c seen in this study are similar 
to those reported in meta-analyses of SMS interventions 
in diabetes not limited to those with poor control.14 16 
41 Unlike previous studies that typically focus on a 
particular population defined by diabetes type, age, or 
treatment, the current study provided an intervention 
for all adults with either type 1 or type 2 diabetes under 
any treatment regimen, enhancing potential reach 
and generalisability. The only limit on the population 
was the requirement that participants had to have 
poor diabetes control. This criterion was particularly 
important given associated costs and debilitating 
complications of poorly controlled diabetes. Although 
few trials so far have examined the effectiveness of 
mHealth interventions in this population,42 this study 
provides evidence to support the use of this modality to 
provide diabetes education and support to individuals 
with poor control.
Table 4 | Treatment effect on secondary outcomes. Data are mean (standard deviation) unless stated otherwise
Secondary outcome
Intervention (n=169) Control (n=172) Adjusted mean  
difference (95% CI)* P for differenceBaseline 9 months Baseline 9 months
Self efficacy (SEDM) 6.94 (1.48) 7.55 (1.33) 6.93 (1.68) 7.44 (1.46) 0.11 (−0.13 to 0.36) 0.36
Diabetes self care behaviours (SDSCA)
 General diet 4.33 (1.98) 4.91 (1.78) 4.37 (2.06) 4.99 (1.79) −0.10 (−0.45 to 0.25) 0.58
 Specific diet 3.84 (1.44) 4.25 (1.39) 3.89 (1.59) 4.19 (1.38) 0.09 (−0.18 to 0.36) 0.50
 Exercise 3.11 (2.15) 3.45 (2.03) 3.27 (2.32) 3.48 (2.19) 0.06 (−0.35 to 0.48) 0.76
 Blood glucose testing 4.38 (2.63) 4.85 (2.57) 4.24 (2.72) 4.85 (2.54) −0.12 (−0.58 to 0.33) 0.59
 Foot care 1.93 (2.19) 2.75 (2.51) 1.97 (2.17) 1.92 (2.13) 0.85 (0.40 to 1.29) <0.001
Diabetes distress (DDS2) 3.37 (1.50) 3.03 (1.48) 3.44 (1.54) 3.26 (1.56) −0.18 (−0.45 to 0.10) 0.21
Perceptions and beliefs about diabetes (BIPQ)
 Consequences 5.38 (2.72) 5.24 (2.76) 4.92 (2.79) 5.42 (2.78) −0.34 (−0.86 to 0.18) 0.20
 Timeline 9.06 (1.72) 9.05 (1.99) 8.61 (2.37) 8.72 (2.18) 0.22 (−0.19 to 0.62) 0.29
 Personal control 5.84 (2.23) 6.84 (2.10) 6.09 (2.39) 6.81 (2.10) 0.10 (−0.30 to 0.50) 0.62
 Treatment control 8.15 (1.81) 8.62 (1.56) 8.08 (2.03) 8.45 (1.68) 0.15 (−0.18 to 0.49) 0.37
 Identity 5.05 (2.74) 4.62 (2.70) 4.56 (2.78) 4.97 (2.60) −0.54 (−1.04 to −0.03) 0.04
 Concern 7.23 (2.78) 6.55 (2.98) 6.99 (2.88) 6.47 (2.99) −0.04 (−0.57 to 0.50) 0.89
 Emotions 5.36 (3.02) 4.74 (3.17) 4.70 (3.34) 4.90 (3.06) −0.37 (−0.97 to 0.23) 0.23
 Illness comprehensibility 7.65 (2.14) 8.36 (1.60) 7.73 (2.15) 8.24 (1.78) 0.15 (−0.18 to 0.48) 0.38
Health related quality of life (EQ-5D)
 Index 0.83 (0.17) 0.84 (0.17) 0.84 (0.18) 0.84 (0.17) 0.00 (−0.03 to 0.04) 0.81
 Health status VAS 66.24 (19.02) 73.22 (19.88) 70.03 (19.87) 70.03 (19.51) 4.38 (0.44 to 8.33) 0.03
Perceived support for diabetes management
 Overall support 4.75 (1.42) 5.14 (1.11) 4.89 (1.30) 4.94 (1.25) 0.26 (0.03 to 0.50) 0.03
 Appraisal 5.13 (1.29) 5.30 (1.13) 5.20 (1.23) 5.21 (1.17) 0.11 (−0.13 to 0.35) 0.38
 Emotional 5.14 (1.31) 5.30 (1.19) 5.20 (1.18) 5.20 (1.21) 0.11 (−0.13 to 0.35) 0.36
 Advice/information 5.39 (1.05) 5.57 (1.03) 5.33 (1.11) 5.54 (0.89) 0.01 (−0.18 to 0.20) 0.90
*Linear regression model adjusted for baseline outcome, diabetes type, ethnicity, and region.
SEDM=self efficacy for diabetes management; SDSCA=summary of diabetes self care activities; DDS2=diabetes distress scale 2 item; BIPQ=brief illness perceptions questionnaire; VAS=visual 
analogue scale.
Table 5 | Intervention satisfaction and acceptability results (n=169)
Question No (%) of yes responses
Was SMS4BG useful? 161 (95)
Were the messages culturally appropriate? 164 (97)
Were the messages age appropriate? 166 (98)
Would you recommend SMS4BG to others with diabetes? 164 (97)
Did you share the messages with any other people? 85 (50)
Did taking part in this programme help you learn about your diabetes? 120 (71)
Did taking part in this programme impact on how you manage your 
diabetes or help you change your behaviours?
140 (83)
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The control group also experienced a decrease 
in HbA1c from baseline to the nine month follow-
up, and experienced improvements in secondary 
outcomes, which could indicate trial effects. Previous 
research has shown that recruitment to a clinical 
trial alone can result in improvements in HbA1c,43 
but it is not expected that these improvements would 
be sustainable past the initial few months without 
intervention.
Study strengths
Strengths of the current study included its sample 
size, diverse population, very low loss to follow-up, 
pragmatic design, absence of protocol violations, and 
objectively measured primary outcome. Although the 
initial sample size target was not reached, the final 
sample of 366 participants is larger than previous 
randomised controlled trials in this area. This study 
contributes valuable evidence to the literature on 
the use of text messages in diabetes particularly for 
individuals with poor control. Considering poorer 
outcomes are experienced by ethnic minority groups, 
a strength of this study was its high proportion of 
participants representing these groups.
Strengths of the intervention were that it was 
theoretically based, the information reinforced 
messages from standard care, and it was system 
initiated, personally tailored, and used simple 
technology. These strengths result in high relevance to 
diverse individuals, increasing the intervention’s reach 
and acceptability. Unlike SMS4BG, previous diabetes 
SMS programmes have largely focused on specific 
groups—for example, limiting their generalisability. 
Furthermore, the SMS4BG intervention was tailored 
and personalised to the individual. Although this 
specificity results in a more complex intervention in 
relation to its delivery, it appears to be a worthwhile 
endeavour with high satisfaction and the majority of 
participants happy with their message dosage.
Study limitations
The  biggest  study  limitation  was  the  difficulty  with 
recruitment, which resulted in a sample size smaller 
than initially planned. One reason for the low 
recruitment was the required time needed by clinicians 
to identify and refer patients to the study, which was 
not always available. Furthermore, many referred 
patients who did not meet the HbA1c inclusion criteria 
were still referred because clinicians had thought 
these individuals would benefit from the programme. 
This limitation highlights the difference between 
research and implementation where strict criteria can 
be relaxed. Alternative methods of recruitment could 
be explored, such as through laboratory test facilities 
to ensure access to the intervention regardless of 
clinician availability.
Owing to time restrictions, longer term follow-up of 
participants was not feasible within the current study, 
although it is hoped that a two year follow-up of the 
present study’s participants is possible. The significant 
group difference seen at three months, dropping 
slightly at six months, but reaching significance again 
at nine months, could be an indication of sustained 
change. Another limitation of the study design was 
that secondary outcome assessors were not blinded to 
treatment allocation, which could have introduced bias 
in follow-up data collection of secondary variables.
SMS4BG was delivered in the English language 
(with the exception of some Māori, Samoan, and 
Tongan words). With high rates of diabetes in ethnic 
minority groups, delivery of this type of intervention in 
languages native to these groups could provide greater 
benefit. It is likely that some people were not referred 
to the study, or were unable to take part, due to the 
criteria that they must be able to read English. SMS 
health programmes have been translated into other 
languages such as Te Reo;44 thus, further research 
needs to look at whether such translations would be of 
benefit in SMS4BG.
Implications
This study shows the potential of SMS4BG to provide a 
low cost, scalable solution for increasing the reach of 
diabetes self management support. It showed that a text 
messaging programme can increase a patient’s feelings 
of support without the need for personal contact from a 
healthcare professional. Half of the intervention group 
reported sharing the messages with others. Traditional 
education for diabetes self management is delivered 
to individual patients, but there is benefit of support 
from other people being involved.45 This is particularly 
pertinent to ethnic populations such as Māori groups, 
in whom family have an important role in supporting 
diabetes self management.46
With technology advancing rapidly, there is a 
call for mHealth to move towards more complex 
technology. However, this study has shown that text 
messaging—available on any mobile phone—although 
simple, is still potentially effective for improving 
glycaemic control. Equally, this study had very few 
technical  difficulties,  which  probably  contributed 
to the high satisfaction with the intervention. The 
individual tailoring of the intervention, and ability 
for participants to choose varying components and 
dosages, means that questions remain around the 
ideal duration for implementation as well as the 
components most important for effectiveness. Further 
research is needed to understand the components of 
this intervention that are most effective and the ideal 
intervention dosage to further refine this intervention 
and inform the development of future interventions. 
With participants highly satisfied with the intervention 
and largely happy with their intervention dosage, but 
great variance in the modules, durations, and dosages, 
SMS4BG may need to remain individually tailored in 
this way, resulting in a more complex intervention 
for delivery until further investigation on this can be 
made.
Conclusions
This study showed that a tailored and automated SMS 
self management support programme has potential 
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for improving glycaemic control in adults with poorly 
controlled diabetes. Although the clinical significance 
of these results is unclear, and the full duration of these 
effects is yet to be determined, exploration of SMS4BG 
to supplement current practice is warranted.
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